Pierpaolo Biondetti, Carolina Lanza, Serena Carriero, Francesca Arrigoni, Margherita Bevilacqua, Aurora Ruffino, Sonia Triggiani, Adriana Sorce, Andrea Coppola, Anna Maria Ierardi, Massimo Venturini, Giuseppe Guzzardi, Gianpaolo Carrafiello
PURPOSE: The aim of this study was to describe the safety and efficacy profiles of TACE using DC Beads LUMI. MATERIALS AND METHODS: We retrospectively analyzed 90 patients with HCC who underwent TACE with DC Bead LUMI™ between November 2018 and November 2020 at Fondazione IRCCS Cà Granda Policlinico Hospital in Milan, Italy. Patient- and tumour-related factors were registered, including the number of treated lesions, dose of DC Beads LUMI™, dose of Epirubicin, DC Beads LUMI™ target tumour coverage (LC) according to the percentage of target nodule involvement (LC1-0%-25%, LC2-25%-50%, LC3-50%-75%, LC4 75%-100%)...
2023: Technology in Cancer Research & Treatment